Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Shattuck Labs, Inc. (STTK) filed a Form 8-K reporting board-related governance updates. The filing notes a Non-Employee Director Compensation Policy and states that Dr. Baker and Dr. Ashiya intend to enter the company’s standard form of indemnification agreement. The agreement for Dr. Ashiya will be modified to reflect her status as an OrbiMed Designee, as defined in the filing. The 8-K references a press release dated August 26, 2025 and also confirms that the 8-K, including the press release attached as Exhibit 99.1, will not be deemed incorporated by reference into filings under the Exchange Act or the Securities Act.
Shattuck Labs (STTK) reported lower operating losses and trimmed R&D activity as it pivots to its DR3 antagonist program SL-325. Cash and cash equivalents were $50.5 million and total assets were $64.4 million at June 30, 2025, while accumulated deficit stood at $407.9 million. For the six months ended June 30, 2025 the company recognized a net loss of $26.2 million, an improvement from $40.1 million a year earlier, driven by a reduction in research and development expense after winding down SL-172154 activities and completing collaboration services in 2024.
Management states current cash is sufficient to fund operations for at least twelve months. The company expects to initiate enrollment in a Phase 1 trial of SL-325 in the third quarter of 2025 and complete enrollment in the full Phase 1 by the second quarter of 2026. In a subsequent event, Shattuck announced a securities purchase agreement expected to provide approximately $46 million in upfront gross proceeds upon closing following IND clearance for SL-325, with additional potential proceeds if warrants are exercised.
Shattuck Labs, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025. The 8-K states the press release is provided as Exhibit 99.1 and clarifies that the information is furnished (not "filed") for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings except by specific reference. The filing confirms the company trades as STTK on The Nasdaq Global Select Market and that it is designated as an emerging growth company.
The 8-K contains no financial figures or discussion of results within the form itself and provides an exhibit listing and signature by CEO Dr. Taylor Schreiber. No additional operational or transaction details are included in this report.
Amendment No. 3 to Schedule 13D filed by Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments II, L.P. discloses beneficial ownership and a private placement related to Shattuck Labs, Inc. (Common Stock, CUSIP 82024L103).
The Reporting Persons report beneficial ownership of 5,652,660 shares (11.8% of the class) based on 47,903,215 shares outstanding as of May 14, 2025. Holdings include 3,338,997 shares held by RBI II and specified holdings in multiple Redmile-managed funds. The filing states Redmile may be deemed to beneficially own 3,100,823 shares issuable upon exercise of Pre-Funded Warrants but those are entirely limited by a 9.99% Beneficial Ownership Blocker and thus excluded from the reported aggregate. The filing also notes 112,936 options exercisable within 60 days held by a Redmile managing director and assigned to Redmile.
On August 4, 2025 the Issuer entered a Purchase Agreement providing for a private placement of Pre-Funded Warrants and accompanying Common Warrants to purchase up to 4,097,730 shares (combined), at a combined price of $0.8676 per paired instrument; RBI II is to purchase 2,048,423 Pre-Funded Warrants and 2,048,423 Common Warrants. The closing is subject to satisfaction or waiver of several conditions including regulatory clearance of the Issuer's IND by the FDA. A side letter grants Redmile pro rata participation rights in future equity offerings and the right to designate a non-voting board observer, subject to maintaining certain ownership.